Edited by Peter Cresswell, Yale University School of Medicine, New Haven, CT, and approved January 12, 2016 (received for review October 8, 2015) Peptide loading of major histocompatibility complex class I (MHC-I) molecules is central to antigen presentation, self-tolerance, and CD8 + T-cell activation. TAP binding protein, related (TAPBPR), a widely expressed tapasin homolog, is not part of the classical MHC-I peptide-loading complex (PLC). Using recombinant MHC-I molecules, we show that TAPBPR binds HLA-A*02:01 and several other MHC-I molecules that are either peptide-free or loaded with low-affinity peptides. Fluorescence polarization experiments establish that TAPBPR augments peptide binding by MHC-I. The TAPBPR/MHC-I interaction is reversed by specific peptides, related to their affinity. Mutational and small-angle X-ray scattering (SAXS) studies confirm the structural similarities of TAPBPR with tapasin. These results support a role of TAPBPR in stabilizing peptide-receptive conformation(s) of MHC-I, permitting peptide editing.
antigen presentation | peptide loading | major histocompatibility complex | protein interactions | SAXS A daptive T-cell responses to intracellular pathogens and tumor antigens are governed primarily by effector CD8 + T cells that recognize antigenic peptides. These peptides are generated by protein degradation or during translation and are presented at the cell surface by MHC-I molecules (1) (2) (3) (4) (5) (6) (7) . The steps of antigen processing and presentation via the MHC-I pathway have been studied extensively, and the contributions of components of the peptide-loading complex (PLC), tapasin, endoplasmic reticulum protein 57 (ERp57), transporter associated with antigen processing (TAP), and calreticulin, as well as various endoplasmic reticulum-associated proteases (ERAAP, ERAP1/2, IRAP) have been elucidated by genetic and biochemical studies (8) (9) (10) (11) (12) . The general features of peptide loading onto MHC-I depend upon proteasome processing in the cytoplasm (13) , transport of peptides to the endoplasmic reticulum (ER) (14) , amino-terminal trimming of peptides (15) (16) (17) , and stabilization of peptide-receptive MHC-I by tapasin (9) and calreticulin (10) . The role of tapasin as a chaperone mediating loading and editing of high-affinity peptides is clear, but the precise molecular mechanism by which tapasin performs these functions remains poorly understood (18) (19) (20) (21) . Amino acid residues of tapasin and MHC-I involved in the interaction have been identified by mutational studies (9, 20, (22) (23) (24) (25) (26) (27) , and the X-ray crystallographic structure of a complex of tapasin and ERp57 provides key information for understanding tapasin (27) . A human gene encoding a tapasin homolog, TAP binding protein, related (TAPBPR), was identified on chromosome 12 (12p13.3) (28, 29) . The encoded type I membrane protein is expressed in the ER and Golgi and interacts with MHC-I during its maturation (30) (31) (32) (33) . TAPBPR is highly conserved among vertebrates (mouse and human proteins are 69% identical), is widely expressed, is inducible by IFN-γ, and coprecipitates with MHC-I molecules containing β 2 -microglobulin (β 2 m) (30), but not with components of the PLC. Results of site-directed mutagenesis of both HLA-A2 and TAPBPR are consistent with a view that tapasin and TAPBPR share a similar mode of MHC-I binding (31) . The amino acid sequence and biochemical similarities to tapasin suggest that examination of the direct interactions of TAPBPR with MHC-I would not only reflect on the normal function of this molecule, but would also provide insight into the molecular mechanisms that govern tapasin. With these goals in mind, we have examined the binding interactions of recombinant human TAPBPR with human and murine MHC-I molecules, performed low-resolution structural studies of both tapasin and TAPBPR in solution, and exploited this information to illuminate the mechanism by which TAPBPR functions in peptide editing.
Results
Binding of TAPBPR to Peptide-Free MHC-I/β 2 m Complexes by Native Gel Shift and Size Exclusion Chromatography. Because previous studies indicated that TAPBPR first interacts with MHC-I early in its biosynthesis (30, 31, 33) , we investigated whether recombinant TAPBPR would bind peptide-free MHC-I with high affinity.
Significance
This report explores the biochemical and structural basis of the interactions of TAP binding protein, related (TAPBPR), a tapasin homolog, with MHC-I molecules. TAPBPR associates with MHC-I molecules early in their biosynthesis and folding but is not part of the peptide-loading complex (PLC). Here, by examining the interactions of recombinant TAPBPR with peptide-free and peptide-complexed MHC-I molecules, we show that TAPBPR serves as a peptide editor. Structural comparison of TAPBPR with tapasin indicates the similarities of the two molecules and provides a basis for evaluating the steps of peptide loading. Understanding the molecular underpinnings of peptide loading of MHC-I by TAPBPR and tapasin has wide-ranging influence on our ability to modulate peptide loading for vaccine design and T-cell recognition. 2) , HLA-A2 (lanes 5 and 6), TAPBPR (lanes 7 and 8), and mixtures of tapasin and HLA-A2 (lanes 3 and 4) or TAPBPR and HLA-A2 (lanes 9 and 10) were separated on native gel with (lanes 2, 4, 6, 8, and 10) or without (lanes 1, 3, 5, 7, and 9) UV irradiation as described in Materials and Methods (4 μg of each protein in 10 μL). The positions of migration of the individual components are indicated, and the shifted TAPBPR/HLA-A2 complex band is denoted with a line. (Lanes 1-4 and 5-10, respectively, were taken from different gels run in parallel.) (B) SEC analysis. Individual components, TAPBPR (green), HLA-A2/photoFluM1 58-66 (magenta), and the mixture of TAPBPR and HLA-A2 after UV irradiation (blue) were analyzed by SEC (S200 HR10/300) as described in Producing peptide-free recombinant MHC-I is difficult for most MHC-I alleles because such molecules are unstable and aggregate (34) . We produced MHC-I complexes refolded with photosensitive peptides and generated peptide-free molecules by UV irradiation (35) . The interaction of peptide-containing, or peptidefree MHC-I with either tapasin or TAPBPR was evaluated in a gel shift assay (Fig. 1A) . For this experiment, HLA-A2 was complexed with human β 2 m (hβ 2 m) and a peptide, photo-FluM1 58-66 (35) (see Table S1 for list of peptides used; peptides containing a photosensitive amino acid are designated by the prefix "photo").
As shown in Fig. 1A, tapasin (lanes 1 and 2) , TAPBPR (lanes 7 and 8), and HLA-A2 (lanes 5 and 6) either before or after UV irradiation have characteristic mobilities in this gel system. The mixture of tapasin and HLA-A2 showed no difference in mobility following UV exposure (lanes 3 and 4), but the mixture of TAPBPR and HLA-A2 showed evidence of their physical association (compare lanes 9 and 10). The gel shift assay, although suggestive of an interaction between UV-irradiated HLA-A2/photo-FluM1 58-66 and TAPBPR, was confirmed and extended by size exclusion chromatography (SEC) analysis of a mixture of UV-irradiated HLA-A2/photo-FluM1 58-66 and TAPBPR (Fig. 1B) . In this chromatographic system, TAPBPR and HLA-A2 elute at ∼19 and 20.5 min, respectively. The irradiated mixture shows a new peak eluting at 18 min, suggestive of an HLA-A2/TAPBPR complex, which was confirmed by SDS/PAGE (Fig. 1C) . Tapasin and HLA-A2, treated in the same way, showed no evidence of association by the SEC assay (Fig. 1D) . [TAPBPR/ HLA-A2 complexes formed following irradiation contained no detectable photo-FluM1 58-66 , and the 7-mer amino-terminal product of photolysis was only found at a level equivalent to 5% of the starting material (Materials and Methods and Table S2 ), indicating that the HLA-A2 in the observed complex with TAPBPR is largely devoid of bound peptide.]
Binding of TAPBPR to HLA-A2 by Sedimentation Velocity-Analytical Ultracentrifugation. The interaction of TAPBPR with HLA-A2 following photolysis of the photo-FluM1 58-66 peptide (Table S1) Binding of TAPBPR to HLA-A2 by Surface Plasmon Resonance. To explore further the interactions of various HLA-A2/peptide complexes to TAPBPR, we used surface plasmon resonance (SPR), which offers a sensitive method to examine molecular interactions in real time ( Fig. 2A) . Although HLA-A2 refolded with either HBV [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] or with FluM1 58-66 showed very little binding, complexes prepared with photo-FluM1 58-66 , even without irradiation, bound appreciably higher, with a dissociation rate (t 1/2 ) of about 200 s ( Fig. 2A , "wash" at t = 425-835 s, blue line). This prompted us to test whether the dissociation of HLA-A2 from TAPBPR would be accelerated by exposure to a highaffinity peptide, such as HBV [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . Indeed, when HBV [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] was included in the washout buffer, HLA-A2 dissociated much more rapidly and completely with a t 1/2 that was too rapid for quantitative estimation ( Fig. 2A , "peptide" at t = 825 s, blue line). To gain a quantitative estimate of the binding of HLA-A2/photoFluM1 58-66 to TAPBPR, without irradiation, graded concentrations were offered to the TAPBPR-coupled surface (Fig. 2B ). These kinetic binding curves could not be fit to a simple A + B ↔ AB model, suggesting a more complex association mechanism or structural heterogeneity of MHC molecules refolded with photolabile peptides. However, analysis of the equilibrium binding data with SEDPHAT (36) provided an estimate of the K d value of 4.73 μM (Cl, 3.67, 6.23), similar to the value obtained with unirradiated components by SV-AUC (1.11 μM). Remarkably, HLA-A2 complexed with photo-FluM1 58-66 , without irradiation showed rapid binding to the TAPBPR surface during the association phase, with relatively rapid dissociation during the buffer washout ( Fig. 2 A and B, "wash"). To evaluate the role of specific peptide in the dissociation phase, HLA-A2/photo-FluM1 58-66 binding to TAPBPR was tested with sequential washouts (Fig. 2C) . Following binding and a brief buffer wash (t = 400 s), exposure to the high-affinity HBV 18-27 peptide (Fig. 2C , at t = 425 s, blue tracing), but not to a nonbinding control peptide (red), elicited a rapid dissociation from TAPBPR. Additional high-affinity peptide (Fig. 2C , at t = 835 s, "high dose") caused rapid release of the residual bound HLA-A2 from TAPBPR. These binding experiments suggested that HLA-A2/photo-Flu-M1 58-66 can bind TAPBPR, but do not eliminate the possibility that a proportion of molecules in the HLA-A2/photo-Flu-M1 58-66 preparation are in a peptide-free state. The acceleration of HLA-A2 dissociation from the TABPBR surface by high-affinity peptide was consistent with the view that TAPBPR binds poorly or not at all to HLA-A2 complexed with high-affinity peptides.
We then compared several different MHC-I complexes prepared with photosensitive peptides without irradiation for binding to the TAPBPR biosensor surface (Fig. 2D) . Although HLA-A1/photo-A1 motif failed to bind at all, several other molecules, including the mouse MHC molecules H2-
, and H2-D b , bound to different levels and dissociated at different apparent rates (Fig. 2D , "wash"). [A mixture of peptides that bind the five MHC-I molecules elicited rapid dissociation of the complexes from the TAPBPR surface (Fig. 2D, "peptide" ).] We then compared the binding of HLA-A2 loaded with different photosensitive peptides with their nonphotosensitive counterparts with or without prior UV irradiation (Fig. 2 E-G) . As noted in Fig. 2A , the HLA-A2/FluM1 58-66 complex barely binds to TAPBPR (Fig. 2E, red) and HLA-A2/HBV 18-27 fails to bind (Fig. 2F, red) . However, even without irradiation, HLA-A2 complexes made with the photosensitive variants of the FluM1 58-66 and HBV [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] peptides bind appreciably ( Fig. 2 E and F, green) and, following irradiation, also bind well ( Fig. 2 E and F, blue) . The increase in binding due to irradiation is greater for the photo-HBV [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] peptide than for photo-FluM1 58-66 . The mouse MHC-I molecule, H2-D d , complexed with a high-affinity peptide P18-I10 or its photosensitive analog, photo-P18-I10, with or without irradiation, revealed interaction with TAPBPR (Fig. 2G, all  tracings) . The apparent kinetic dissociation rate of irradiated H2-D d /photo-P18-I10 from TAPBPR (Fig. 2G , blue, "wash") was slower than that of the unirradiated H2-D d /photo-P18-I10 (Fig. 2G , green, "wash"), which in turn was slower than that of the H2-D d /P18-I10 complex (Fig. 2G, red) . Thus, depending on the particular MHC-I molecule and the particular peptide, interaction with TAPBPR can occur even without photolysis of the bound peptide. One possible explanation for the increased ability of HLA-A2 or H2-D d complexed with photosensitive compared with the classical epitopic peptides to bind better to TAPBPR is that these complexes might be more unstable, generating a population of empty or peptide-receptive molecules available for TAPBPR binding. We tested this possibility by examining the thermal stability of HLA-A2 and H2-D d complexed with either the antigenic viral peptides or the photosensitive variants (Fig. S2) . /photo-P18-I10, a T m value of 54.3°C. Although the complexes containing the photosensitive peptides were less thermostable, they were not detectably denatured at temperatures below 40°C. These data are consistent with a view that TAPBPR can interact with peptide-complexed, folded molecules, but do not formally rule out the possibility that the molecules that interact with TAPBPR represent a population of peptide-free molecules in each of these preparations. In some cases (e.g., HLA-A2/FluM1 58-66 , TAPBPR Augments Peptide Exchange. To evaluate the role of TAPBPR in peptide exchange, we compared the ability of free and TAPBPR-bound HLA-A2 to bind a FITC-labeled high-affinity peptide using a fluorescence polarization assay, in which graded concentrations of protein were offered a fixed concentration (10 nM) of fluorescent indicator peptide. As shown in Fig. 3A , the HLA-A2/FluM1 58-66 complex bound the fluorescent indicator peptide FITC-HBV [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] (Table S1) , at a half-maximal protein concentration of about 300 nM. We then purified the TAPBPR/HLA-A2 complex generated by irradiation of a mixture of TAPBPR and HLA-A2/photo-FluM1 58-66 by SEC and tested this for peptide binding. Half-maximal binding was achieved by the purified complex at a 100-fold lower concentration of about 3 nM. A control HLA-B7 peptide, FITC-PAP 277-285 , was not bound by either of the protein preparations. HLA-A2/FluM1 58-66 complexes were exposed to the higher affinity FITC-HBV 18-27 along with graded concentrations of TAPBPR (Fig. 3B) . As TAPBPR concentration increased from 0 to 500 nM, the binding curve shifted to the left, indicating that TAPBPR facilitated the replacement of FluM1 58-66 by FITC-HBV [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . In a more stringent test of the influence of TAPBPR on peptide exchange, HLA-A2 refolded with the higher affinity HBV [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] peptide was tested with graded doses of TAPBPR included in the binding reaction. Increasing TAPBPR from 0 to 500 nM augmented the peptide exchange (Fig. 3C) . The control HLA-B7 binding fluorescent peptide, FITC-PAP 277-285 , failed to exchange onto HLA-A2 even in the presence of TAPBPR (Fig. 3D) . Thus, the TAPBPR augmentation of peptide exchange may be observed either when present as TAPBPR/HLA-A2 complexes, or when provided free to HLA-A2/peptide complexes.
HLA-A2-Binding Peptides Release TAPBPR and HLA-A2 from the Complex in an Affinity-Dependent Manner. The observation that TAPBPR interacts strongly with HLA-A2 after photolysis of bound peptide (Fig. 1B) suggested that TAPBPR might function in peptide loading in a manner similar to tapasin and the PLC. In addition, SPR experiments indicated that cognate peptides could accelerate the dissociation of MHC-I from TAPBPR (Fig. 2) . Addition of free FluM1 58-66 in graded doses to preformed TAPBPR/HLA-A2 complexes resulted in the release of free TAPBPR and HLA-A2 as shown in the gel shift assay (Fig. 4A ) and by SEC (Fig. 4B) . In contrast, a peptide that does not bind HLA-A2 (MCMVpp89 168-176 ) failed to release the components of the complex (Fig. 4 A and C) . To confirm that the TAPBPR/ HLA-A2 complex was released by exposure to HLA-A2-binding peptides, and to address the hypothesis that the dissociation is related to the intrinsic affinity of a peptide for HLA-A2, we screened a set of peptides of known affinity for HLA-A2, using each peptide at a fixed concentration. As shown in Fig. 4D , exposure of the TAPBPR/HLA-A2 complex to free peptide resulted in the dissociation of TAPBPR and HLA-A2 in direct proportion to the known affinity of the peptide for HLA-A2. Using a fluoresceinated version of an HLA-A2-binding peptide as a probe, we established that, on dissociation of TAPBPR from HLA-A2 by high-affinity peptide, the peptide associates with the HLA-A2 but not the TAPBPR component as indicated by the coelution of HLA-A2 (the 280-nm absorbance peak) with the 500-nm FITC-HBV 18-27 absorbance peak (Fig. 4E) . On exposure to a control peptide, no dissociation of the complex or binding to HLA-A2 was observed (Fig. 4F ). Taken together with the SPR and fluorescence polarization results, these experiments are consistent with the view that the TAPBPR/MHC complex, whether in solution or immobilized on a biosensor chip, dissociates as peptide binds to the MHC-I molecule. Site. Previous analysis of site-directed mutants of both tapasin (27) and TAPBPR (31), using transfection and antibody pulldown experiments, mapped the binding site(s) for MHC-I to several patches of the first, second, and third domains, based on amino acid sequence alignment (29) . We have extended these observations by examining recombinant site-directed mutants of TAPBPR in each of its three major domains for their ability to bind HLA-A2/photo-FluM1 58-66 following UV irradiation by the SEC assay. Using mutant assignments originally made for tapasin (27) , we examined several TAPBPR mutants (Fig. 5) . As shown in Fig. 5B , we found that, whereas TAPBPR readily forms a complex with irradiated HLA-A2/photo-FluM1 58-66 (blue), the TN1 mutant (D17K, F19A, magenta) binds detectably but forms less of the high-molecular-weight complex than does parental TAPBPR. Neither TN6 (E205K, R207E, Q209S, Q272S; green) nor TC3 (Q336D, S337D; brown) binds at all. These results indicate that the direct interaction of TAPBPR with peptide-free HLA-A2 is dependent on contributions from the second and third domains and is influenced by residues in the N domain as well. Tapasin and TAPBPR thus share similar modes of binding to MHC-I.
Structure Determination of TAPBPR and Tapasin by Small-Angle X-Ray Scattering. The amino acid sequence similarities of tapasin and TAPBPR, the characteristics of their interactions with MHC-I, and the mutational analyses all support the prediction that they share 3D structural features. Although the structure of tapasin has been determined crystallographically in complex with the oxidoreductase ERp57 (27) , no structural information is available for TAPBPR. To explore further the similarities of tapasin and TAPBPR, we determined both structures at low resolution by small-angle X-ray scattering (SAXS). Data were collected and processed (Table S3) as described in Materials and Methods, giving Guinier fits as shown in Fig. 6 A and B. The radii of gyration R g for tapasin and TAPBPR were 32.9 and 32.3 Å, respectively. The maximum particle sizes, D max , were 98.1 and 97.9 Å, respectively. The pairwise distance distribution function [P(r)] from the observed tapasin data ( Fig. 6C ) (red) compared favorably with that calculated from the tapasin model derived from the X-ray structure (3F8U) (dotted black). The P(r) of TAPBPR ( Fig. 6D ) (cyan) also compared well with the structural homology model of TAPBPR (dotted black) based on the tapasin structure. From the SAXS data, envelopes were calculated and were docked with the X-ray structure for tapasin (Fig. 6E) or with the tapasin-based TAPBPR model (Fig. 6G) . The similarity of the two structures determined by SAXS is supported by the closeness of the R g and D max values, and is readily illustrated by the superposition of the two experimentally determined envelopes (Fig. 6F ). TAPBPR and tapasin are thus clearly related not only in amino acid sequence and in conservation of some interacting residues, but also by their low-resolution 3D structures. The SAXS structure of tapasin indicates that the envelope of the isolated luminal domain in solution closely approximates the X-ray structure of tapasin bound with ERp57, and establishes that the TAPBPR luminal domain maintains a similar solution structure. Thus, TAPBPR likely exploits an MHC recognition surface similar to that used by tapasin and may sterically compete for tapasin binding when MHC-I is accessible to both molecules.
Discussion
TAPBPR is an MHC-I chaperone structurally related to tapasin that coprecipitates with MHC-I molecules but whose function in antigen presentation is unclear. The experiments we report here detailing the molecular interactions between purified soluble TAPBPR and MHC-I molecules demonstrate that (i) the human recombinant TAPBPR luminal domain interacts directly with purified soluble human as well as murine MHC-I molecules;
(ii) the TAPBPR-bound MHC-I molecule is in a peptide-receptive state; (iii) the binding of high-affinity peptide by MHC-I dissociates the TAPBPR/MHC-I complex; and (iv) TAPBPR and tapasin are structurally similar and also share similar modes of binding to their MHC-I ligands. We observed peptide preferences and allele dependencies in the interaction of TAPBPR with MHC-I. HLA-A2, when peptide-free following photolysis of a bound photolabile peptide or when complexed with moderate-affinity peptides (such as photoFluM1 58-66 and photo-HBV 18-27 with or without irradiation), binds to TAPBPR. However, HLA-A2 complexed with the highaffinity HBV 18-27 peptide fails to bind TAPBPR. The preference of TAPBPR for "empty" MHC-I molecules or those loaded with intermediate-or weak-affinity peptides may be related to its peptideediting function. TAPBPR, like its homolog tapasin in the PLC, can permit higher affinity peptides to exchange onto molecules that were previously loaded with weaker binding peptides, or onto molecules that were released from bound photosensitive peptides by photolysis. As shown for tapasin (37) , TAPBPR also demonstrates allelic preferences, as HLA-A1 even when released from a photolysable peptide fails to bind. Human TAPBPR interacts not only with HLA-A2 but also shows broad cross-reactivity with the murine molecules, H2-D . This reflects conservation of crucial structural features of MHC-I molecules necessary for TAPBPR interaction and also the similarities in MHC-I antigen processing and presentation pathways. The variation in the extent of TAPBPR binding to different MHC-I/peptide complexes may reflect differences in the dynamic structure or stability of different MHC-I molecules.
We provide evidence for an editing function of TAPBPR by demonstrating the ability of added TAPBPR to augment peptide exchange in a fluorescence polarization assay and the ability of TAPBPR to stabilize MHC-I molecules in a peptide-receptive form. In addition, the determination of the structural similarity of TAPBPR to tapasin by SAXS and the behavior of mutants in predicted homologous positions to those observed for tapasin suggest that the mechanism of binding and stabilization and the site of binding of MHC-I by TAPBPR is similar to that of tapasin. The chaperone/editing function of TAPBPR, like tapasin, also shows important similarities to the functions of the MHC-II chaperone, HLA-DM, which stabilizes MHC-II molecules by binding to a region of MHC-II on the α1-helix of MHC-II, a position symmetrically related to the site mapped by mutagenesis to MHC-I on the α2-helix (22, 31) . A role of the MHC-I lightchain β 2 m in facilitating peptide exchange has been recognized for many years (37, 38) , likely reflecting the dynamic and cooperative nature of MHC/β 2 m/peptide interactions.
Indeed, the peptide-editing function of tapasin in the PLC is clear (3, 21) , and our results are consistent with a similar function for TAPBPR. However, the biological need for what may appear to be redundant peptide loading/exchange systems (i.e., PLC vs. TAPBPR) remains perplexing. Several differences in the two systems suggest plausible reasons for their evolutionary preservation. Major biochemical differences between the PLC and the TAPBPR system include the following: (i) the PLC is localized to the ER while TAPBPR (which is not glycosylated and lacks any ER retention signal) is also found beyond the medial Golgi (30); (ii) TAPBPR is a single polypeptide chain, whereas the PLC consists of multiple chains ensuring additional chaperone function (by calreticulin), proximity to peptide delivery via TAP, and stabilization by ERp57; (iii) the luminal domain of TAPBPR seems to interact more tightly with susceptible MHC-I molecules than does the luminal domain of tapasin.
Although the studies of TAPBPR interactions with MHC-I to date are limited, taken together they permit us to formulate a mechanistic model of TAPBPR binding and function, which is illustrated schematically in Fig. S3 . This model posits the interaction of TAPBPR (i) with peptide-free MHC/β 2 m complexes early in biosynthesis in the ER; (ii) with low-affinity peptidecontaining MHC/β 2 m complexes either in the ER or a post-Golgi compartment; (iii) with peptide-free MHC/β 2 m complexes in equilibrium with low-affinity peptide-containing complexes; and (iv) conceivably with alternate conformations of high-affinity peptide-containing MHC/β 2 m complexes, which may lead to the rapid dissociation of TAPBPR from the TAPBPR/MHC/β 2 m/ peptide complex.
The particular MHC-I/peptide complexes that interact with TAPBPR may be viewed as a continuum, but three general kinds have been observed: those MHC or MHC/peptide complexes with which TAPBPR fails to interact, irrespective of the assay used (e.g., HLA-A1); those MHC/peptide complexes that contain weakly binding or photosensitive peptides, with or without irradiation (e.g., HLA-A2 with a variety of peptides;
, and H2-D b complexed with photosensitive peptides); or those MHC alleles that bind particularly well even when complexed with high-affinity peptides (e.g., H2-D d ). It is worth noting that the photosensitive peptides that we have used in these experiments contain 3-amino-3-(2-nitro)phenyl-propionic acid, a β-amino acid, that may contribute to a distortion of the MHC/ peptide complex that reads out in greater interaction with TAPBPR. This distortion is reflected in the decreased thermal stability of HLA-A2 and H2-D d when complexed with photolabile peptides. Whether initial interactions of TAPBPR at a molecular level are only with peptide-free MHC-I or with MHC-I/ peptide complexes in particular conformations is a subtle distinction that may require high-resolution binding assays in solution, such as NMR methods, to discriminate.
Following submission of our manuscript, Hermann et al. (39) provided similar findings to our own, offering data indicative of the peptide-editing function of TAPBPR. Extensive data on the ability of TAPBPR to interact with MHC/peptide complexes and to accelerate dissociation of weakly binding peptides, consistent with our own findings, were reported.
Despite our progress in understanding binding aspects of TAPBPR and establishing a low-resolution structural similarity to tapasin, many questions concerning the biochemistry and biology of TAPBPR remain to be explored, including understanding the details of the role that TAPBPR plays in intracellular peptide loading, the dynamics of TAPBPR/MHC association, and the high-resolution structural basis for its peptide-editing functions.
A B The peak corresponding to the assembled complex was recovered, concentrated by ultrafiltration, and subjected to ion exchange chromatography on monoQ 5/50 GL (GE Healthcare Life Science). Protein purity and identity were confirmed by SDS/PAGE and by N-terminal sequencing.
Peptides. Synthetic peptides as listed in Table S1 from Biopeptek or CPC Scientific, were provided as >90% pure, and identity was confirmed by mass spectrometry. Conditional photosensitive peptides were synthesized with one residue replaced by 3-amino-3-(2-nitro)phenyl-propionic acid) designated J* as reported by Toebes et al. (35) . Throughout the text, we refer to peptides containing the J* amino acid with a prefix of "photo" and specifically indicate when these have been irradiated. UV-Mediated Cleavage of Photosensitive Peptides and Mass Spectrometry Analysis. Purified proteins refolded with photolabile peptides were irradiated (366 nm) in a CAMAG UV-illuminator box for 40 min. After UV irradiation, the samples were equilibrated at room temperature for 30 min before further analysis. In some cases, photolysis of peptides was confirmed by reverse-phase HPLC of the MHC molecules refolded with photolysed peptides. For mass spectrometry analysis, size exclusion-purified HLA-A2/TAPBPR complexes were diluted with buffer A (0.1% formic acid in milli-Q water), followed by heating at 95°C for 10 min to dissociate the complex. Samples were loaded onto a Trap-elute jumper chip using an Eksigent Nanoflex cHiPLC system. Each sample was switched onto the microfluidic trap column (ChromXP C18-CL 3 μm, 120 Å, 200 μm × 0.5 mm) to remove the salts and buffer from the sample using an isocratic gradient of 50% B (0.1% formic acid in acetonitrile) for 5 min, at 4 μL·min −1 flow rate. Analytical (ChromXP C18-CL 3 μm, 120 Å, 75 μm × 15 cm) microfluidic column was then switched in line and peptides were separated on a linear gradient eluting with 70% B (0.1 % formic acid in acetonitrile) over 75 min (300 nL·min −1 ). Eluted peptides were directly introduced onto the electrospray ionization source using Nanospray of the Thermo Q-Exactive mass spectrometer (MS). Full MS spectra were recorded at 70,000 resolution, MS/MS spectra were acquired using high-collision energy dissociation ( Table S2 .
Native Gel Shift Assay. Equal amounts of MHC-I/β 2 m complexed with photosensitive peptide were mixed with TAPBPR or tapasin (4 μg of each in 10 μL), UV-irradiated for 40 min at room temperature, and rested for 30 min, and were then analyzed in acrylamide gels devoid of SDS using the MiniProtean system (Bio-Rad), with the Tris-glycine buffer system. The samples were mixed with native gel loading buffer [250 mM Tris (pH 8.8), 10% glycerol], loaded on discontinuous polyacrylamide gels (4% stacking, 13% resolving), and run at 100 V at room temperature for 3.5 h in 25 mM Tris, 190 mM glycine running buffer. Following electrophoresis, proteins were visualized with RAPIDstain (G-Biosciences) or PageBlue Protein staining solution (Thermo Scientific).
SEC. Analytical SEC was performed on either a Superdex S200 HR10/300 or on a Shodex KW802.5 column at a flow rate of 0.75 mL/min, developed under native conditions (PBS, pH 7.3), calibrated with standard molecular-weight markers (Bio-Rad; 1511901).
AUC.
Analytical ultracentrifugation experiments were conducted in an XL-I analytical ultracentrifuge (Beckman Coulter) with an An50Ti rotor, following previously described protocols (44) . Protein samples were prepared by dilution of concentrated stocks with the working buffer (PBS). Individual protein molecules were characterized in the primary AUC experiments with TAPBPR at 2 μM and HLA-A2 refolded with photo-FluM1 58-66 peptide in a concentration series from 0.1 to 10 μM. In an independent experiment, purified TAPBPR and HLA-A2/photo-FluM1 58-66 were irradiated and examined over a range of concentrations. The samples were loaded into standard double-sector charcoal-filled Epon centerpieces with 12-or 3-mm path length and sapphire windows. The sedimentation process of the protein molecules was monitored using both Rayleigh interference and UV absorbance at 280-nm detection at 20°C and 195,000 × g at a radius of 7 cm. The acquired sedimentation velocity data were analyzed with SEDFIT (https://sedfitsedphat.nibib.nih.gov/software) using the c(s) sedimentation coefficient distribution approach (45) , from which the signal weightedaverage sedimentation coefficient (s w ) was obtained by integration. To determine the binding affinity, the isotherm of s w as a function of macromolecular concentrations was loaded into SEDPHAT (https://sedfitsedphat. nibib.nih.gov/software) and fitted with the 1:1 heterodimerization model as follows:
where c A and c B denote the molar concentration of the free species of A and B, respectively, which relate with mass conservation to the total component loading concentrations, s denotes the sedimentation coefficient, and K AB (K D = 1/K AB ) is the equilibrium association binding constant. In the analysis, s A and s B were fixed at the experimentally determined values, whereas K AB and s AB were subject to optimization through nonlinear regression. The error surface projection analysis was exploited to determine the error intervals of the best-fit K D values at a 95% confidence level. The AUC graphs were prepared in GUSSI (biophysics.swmed.edu/MBR/software.html) (46) . Representative sedimentation profiles of TAPBPR, HLA-A2/photo-FluM1 58-66 , and of the mixture following irradiation are given in Fig. S1 .
Fluorescence Polarization. Binding of HLA-A2 (i.e., HLA-A2/peptide complexes) alone or in the presence of graded amounts of TAPBPR, or of HLA-A2/ TAPBPR complexes (previously purified by SEC following UV irradiation and complex formation) to fluorescent peptides was examined by fluorescence polarization using a modification of previously published methods (37) . Individual wells of a black polystyrene 384-well Corning plate were loaded with indicated proteins at concentrations as indicated in the figure legends, to a final volume of 70 μL. Peptide exchange was initiated by addition of 10 μL of 40 nM FITC-labeled peptide. The plates were incubated at 18°C for 12-24 h including appropriate controls for buffer, protein alone, and peptide alone. F P values given as milli-Polarization (mP) are calculated by the following equation: Polarization (mP) = 1,000 (S -GP)/(S + GP), where S and P are background-subtracted intensities of the fluorescence measured in the parallel (S) and perpendicular (P) directions, respectively, and G (grating) is an instrument and assay-dependent correction factor.
SPR Binding Assays and Data Analysis. All SPR experiments were performed on a BIAcore T100 Biosensor (BIAcore) at 25°C in 10 mM Hepes, pH 7.4, 150 mM NaCl, and 3 mM EDTA. About 1,000 response units (RU) of purified recombinant TAPBPR were immobilized on a research-grade CM5 chip (BIAcore) with 1-ethyl-3- SAXS. Models of the structural shapes of unliganded TAPBPR and tapasin were determined by SAXS data analysis. SAXS data were collected at beamline BioCAT (18ID-D) at the Advanced Photon Source at the Argonne National Laboratory. Purified TAPBPR or tapasin was run in-line on a Superdex 200 Increase 10/300 column at a flow rate of 0.75 mL/min directly connected to the sample chamber, and images were collected during 1-s exposures. Two-dimensional diffraction images were reduced to onedimension scattering data, and buffer scattering was subtracted. Data analysis and radius of gyration (R g ) and pairwise distance distribution function P(r) calculations were performed using PRIMUS (48) , and dummy residue models were produced using DAMMIN/DAMMIF (49, 50) . SAXS envelopes were produced by pdb2vol of SITUS (situs.biomachina.org), and rendered by VMD (www.ks.uiuc.edu/Research/vmd/). A comparison of R g and fitness between PDB structures and derived models and the SAXS experimental data were made with CRYSOL (51) . SAXS data and models have been deposited in the BioIsis database (www.bioisis.net) under ID codes TAPSNP and TAPBPP. Data collection and scattering-derived parameters are shown in Table S3 .
